Research programme: flavivirus therapeutics - Idenix

Drug Profile

Research programme: flavivirus therapeutics - Idenix

Latest Information Update: 30 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AFMB; CNR; CNRS; ESIL; Idenix Pharmaceuticals; University of Cagliari; University of Montpellier II; University of Osnabruck
  • Developer CNR; CNRS; Idenix Pharmaceuticals; University of Cagliari; University of Osnabruck
  • Class
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Flavivirus infections

Most Recent Events

  • 31 Dec 2004 Discontinued - Preclinical for Flavivirus infections in France (unspecified route)
  • 31 Dec 2004 Discontinued - Preclinical for Flavivirus infections in Germany (unspecified route)
  • 31 Dec 2004 Discontinued - Preclinical for Flavivirus infections in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top